Publications by authors named "Mary-Ellen Taplin"

100Publications

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

J Clin Oncol 2020 Aug 9;38(24):2798-2811. Epub 2020 Jun 9.

Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430215PMC
August 2020

Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies.

Hum Pathol 2020 05 11;99:62-74. Epub 2020 Mar 11.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.03.001DOI Listing
May 2020

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Eur Urol 2020 04 27;77(4):508-547. Epub 2020 Jan 27.

University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.01.012DOI Listing
April 2020

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Prostate Cancer Prostatic Dis 2020 03 3;23(1):66-73. Epub 2019 May 3.

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0152-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825875PMC
March 2020

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Prostate Cancer Prostatic Dis 2019 09 14;22(3):420-427. Epub 2019 Jan 14.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0121-2
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0121-2DOI Listing
September 2019

Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men.

JAMA 2018 12;320(23):2479-2481

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.11716DOI Listing
December 2018

Downregulation of Accelerates Progression to Castration-Resistant Prostate Cancer.

Cancer Res 2018 11 21;78(22):6354-6362. Epub 2018 Sep 21.

Department of Medicine and Cancer Center, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239953PMC
November 2018

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Am Soc Clin Oncol Educ Book 2018 May;38:363-371

From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200967
Publisher Site
http://dx.doi.org/10.1200/EDBK_200967DOI Listing
May 2018

Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.

Cancer Lett 2018 12 11;438:97-104. Epub 2018 Sep 11.

Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2018.09.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186500PMC
December 2018

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.

J Clin Oncol 2018 09 20;36(25):2639-2646. Epub 2018 Jul 20.

Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Michael Borre, Aarhus University Hospital, Aarhus, Denmark; Howard Gurney, Macquarie University, Sydney, New South Wales, Australia; Yohann Loriot, Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U981, University of Paris Saclay, Villejuif, France; Corina Andresen-Daniil, Ranjith Kalleda, and Trinh Pham, Pfizer, New York, NY; and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118405PMC
September 2018

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.

J Endocr Soc 2018 May 20;2(5):485-496. Epub 2018 Apr 20.

Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/js.2018-00039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941157PMC
May 2018

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Eur Urol 2018 08 22;74(2):146-154. Epub 2018 Feb 22.

Harvard Medical School, Boston, MA, USA; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.01.043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615042PMC
August 2018

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

J Urol 2018 04 10;199(4):990-997. Epub 2018 Jan 10.

American Urological Association Education and Research, Inc., Linthicum, Maryland; ASTRO, Arlington, Virginia; Society of Urologic Oncology, Schamburg, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.01.002DOI Listing
April 2018

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.

JCO Precis Oncol 2017 11;1. Epub 2017 Dec 11.

, , , , , , , , and , Dana-Farber Cancer Institute; , , , and , Brigham and Women's Hospital; and , Beth Israel Deaconess Medical Center, Boston; , , , , , , , and , Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; and , University of California San Diego, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446377PMC
December 2017

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

J Urol 2018 03 15;199(3):683-690. Epub 2017 Dec 15.

American Urological Association Education and Research, Inc., Linthicum, Maryland; ASTRO, Arlington, Virginia; Society of Urologic Oncology, Schamburg, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.11.095DOI Listing
March 2018

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.

J Urol 2017 12 20;198(6):1324-1332. Epub 2017 Jul 20.

Oregon Health & Science University Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.07.071DOI Listing
December 2017

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Endocr Relat Cancer 2017 08 29;24(8):393-404. Epub 2017 Jun 29.

Department of Systems Pharmacology & Translational TherapeuticsPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-17-0107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593253PMC
August 2017

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.

J Clin Oncol 2017 Jun 25;35(17):1952-1964. Epub 2017 Apr 25.

Katherine S. Virgo, Emory University, Atlanta, GA; Ethan Basch, University of North Carolina, Chapel Hill, NC; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto; Eric Winquist, London Health Sciences Centre, London, Ontario, Canada; Thomas K. Oliver and R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Michael A. Carducci, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Luke Nordquist, Urology Cancer Center and GU Research Network, Omaha, NE; Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA; and Eric A. Singer, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.8030DOI Listing
June 2017

Prostate cancer: Developing novel approaches to castration-sensitive disease.

Cancer 2017 Jan 1;123(1):29-42. Epub 2016 Nov 1.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30329DOI Listing
January 2017

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.

Clin Genitourin Cancer 2017 04 20;15(2):e289-e298. Epub 2016 Aug 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.08.015DOI Listing
April 2017

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Clin Cancer Res 2016 07 2;22(14):3672-82. Epub 2016 Mar 2.

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts. Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947432PMC
July 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

EBioMedicine 2015 Nov 8;2(11):1814-20. Epub 2015 Sep 8.

Department of Biostatistics and Bioinformatics, and Alliance Statistics and Data Center, Duke University, Durham, NC, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.09.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740313PMC
November 2015

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors.

Clin Cancer Res 2016 05 2;22(9):2183-9. Epub 2015 Dec 2.

Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854770PMC
May 2016

Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?

JAMA Oncol 2015 Aug;1(5):577-9

Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts3Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1457DOI Listing
August 2015

Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!

Histopathology 2016 Jan 14;68(2):303-7. Epub 2015 Jul 14.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12739DOI Listing
January 2016

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Eur Urol 2015 Nov 16;68(5):795-801. Epub 2015 Feb 16.

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.01.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013546PMC
November 2015

(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.

Am J Nucl Med Mol Imaging 2015 15;5(1):72-82. Epub 2014 Dec 15.

Dana-Farber Cancer Institute, Harvard Medical School Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299771PMC
January 2015

Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.

Clin Genitourin Cancer 2015 Aug 31;13(4):e325-e328. Epub 2014 Dec 31.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563804PMC
August 2015

The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

Chem Biol Interact 2015 Jun 13;234:332-8. Epub 2014 Dec 13.

Centers for Cancer Pharmacology and Excellence of Environmental Toxicology (CEET), Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00092797140039
Publisher Site
http://dx.doi.org/10.1016/j.cbi.2014.12.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414681PMC
June 2015

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Clin Genitourin Cancer 2015 Apr 22;13(2):113-23. Epub 2014 Oct 22.

Medical Oncology, Dana-Farber Cancer Institute and Internal Medicine, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418946PMC
April 2015

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

J Clin Oncol 2014 Nov 13;32(33):3705-15. Epub 2014 Oct 13.

Mary-Ellen Taplin, Massimo Loda, Rosina T. Lis, Wanling Xie, Zhenyang Jiang, and Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School; Glenn J. Bubley, Huihui Ye, and Steven P. Balk, Beth Israel Deaconess Medical Center; Jerome P. Richie, Massimo Loda, and Rosina T. Lis, Brigham and Women's Hospital, Boston, MA; Bruce Montgomery, Bruce L. Dalkin, Lawrence D. True, and Alvin M. Matsumoto, University of Washington; Brett T. Marck and Alvin M. Matsumoto, Geriatric Research, Education and Clinical Center, Veterans' Affairs Puget Sound Health Care System; Elahe A. Mostaghel and Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA; Christopher J. Logothetis, John W. Davis, and Patricia Troncoso, University of Texas MD Anderson Cancer Center, Houston, TX; Martin G. Sanda, Emory University School of Medicine, Atlanta, GA; Massimo Loda, King's College London, London, United Kingdom; Trevor M. Penning and Daniel Tamae, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and Christopher M. Haqq, NamPhuong Tran, Weimin Peng, Thian Kheoh, and Arturo Molina, Janssen Research and Development, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.4578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226804PMC
November 2014

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

J Clin Oncol 2014 Oct 8;32(30):3436-48. Epub 2014 Sep 8.

Ethan Basch, Ronald C. Chen, and Stacie B. Dusetzina, University of North Carolina, Chapel Hill; Derek Raghavan, Carolinas Health Care/Levine Cancer Institute, Charlotte, NC; D. Andrew Loblaw, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Ted Wootton, Patient Representatives, Toronto; Sebastian Hotte and Cindy Walker-Dilks, McMaster University; Cindy Walker-Dilks, Cancer Care Ontario, Hamilton; Eric Winquist, London Health Sciences Centre, London, Ontario; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Thomas K. Oliver and R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Michael Carducci, Johns Hopkins University, Baltimore, MD; James N. Frame, Charleston Area Medical Center Health Systems, Charleston, WV; Kristina Garrels, Private Practice, Fargo, ND; Michael W. Kattan, Cleveland Clinic, Cleveland, OH; Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA; James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA; Charles L. Bennett, South Carolina College of Pharmacy, Columbia, SC; and Katherine S. Virgo, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.8404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876355PMC
October 2014

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

J Clin Oncol 2014 Jun 12;32(18):1889-94. Epub 2014 May 12.

Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C. Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J. Sweeney, Mary-Ellen Taplin, Adam S. Kibel, Katherine M. Krajewski, Philip W. Kantoff, Robert W. Ross, and Jonathan E. Rosenberg, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Christopher Tretter, Lahey Clinic, Burlington; Glenn J. Bubley, Beth Israel Deaconess Medical Center, Boston, MA; Leonard J. Appleman, University of Pittsburgh, Pittsburgh, PA; and Jonathan E. Rosenberg, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.4785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057274PMC
June 2014

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014